Compared to DPP4i users, those using SGLT2i and GLP1a were more likely to be of younger age; were less likely to have cardiovascular disease; had higher BMI and HbA1c levels; and were more likely to have insulin use. The gene discussed is INS; the disease is cardiovascular disorder.